Fujifilm buys ProSolv
Fujifilm Medical Systems USA has completed the purchase of Indianapolis, Ind.-based cardiology PACS vendor Problem Solving Concepts (aka ProSolv). The company will now be known as ProSolv CardioVascular, and will operate as a wholly owned subsidiary of Fujifilm Corp. The move will bolster Fuji’s combined radiology and cardiology offerings.
Combined with Fujifilm’s worldwide PACS development headquarters in Stamford, Conn., ProSolv’s tools will enable Fujifilm to extend its enterprise information management approach to now include cardiology, and to provide a broader array of integrated technology solutions to a rapidly growing market. ProSolv CardioVascular Enterprise PACS solution is currently installed at approximately 350 sites.
“The need for more tightly integrated enterprise image and information systems, combined with the growing application of CT and MR into cardiac applications, necessitates that we continually evolve our products and the way we do business to most effectively provide solutions for our customers who are at the cutting edge of these changing markets,” said Makoto Kawaguchi, president and CEO, Fujifilm. “The acquisition of ProSolv enables Fujifilm to strengthen our existing product portfolio and our foundation for growth, and exemplifies FUFJILM Corporation’s long term commitment in the healthcare arena.”
ProSolv Founder and President Tom Feigenbaum said, “With the growing needs of our customers, combined with recent industry consolidation, we saw this as an opportune time to align with one of the industry leaders in PACS. Fujifilm will provide the additional resources that are necessary to ensure that our current and future customers alike continue to receive a stream of innovative clinical features backed by high quality support.” Feigenbaum will remain with ProSolv CardioVascular.
Investment and expansion in new clinical areas such as cardiology is one in a number of milestones for Fujifilm, and acquisition of ProSolv is an important step in delivering that complete vision.
The Synapse and ProSolv software applications share similar software technology approaches that have already enabled rapid systems integration, providing enhanced access to all clinical imaging data for customers using both products. The companies believe that with the integrated capabilities of the clinicians will see improved levels of efficiency and cost savings in the IT space from a uniform approach to storage and disaster recovery solutions.
“Fujifilm’s acquisition of ProSolv affords great opportunity for all of our customers,” said Bob Cooke, executive director of Marketing and Product Management, Fujifilm. “By combining the stability and corporate depth of Fujifilm, a proven leader in radiology PACS, with the cardiology expertise of ProSolv, both of our customer bases will benefit from access to new resources and technologies for the delivery of more effective patient care. This is yet another exciting step in our corporate and product evolution and will markedly enhance both our position in the market as well as our ability to continually deliver leading products.”
This is the first acquisition that FUJIFILM has made since launching the Synapse program and demonstrates, the company said, its commitment to a diverse expansion strategy.
Combined with Fujifilm’s worldwide PACS development headquarters in Stamford, Conn., ProSolv’s tools will enable Fujifilm to extend its enterprise information management approach to now include cardiology, and to provide a broader array of integrated technology solutions to a rapidly growing market. ProSolv CardioVascular Enterprise PACS solution is currently installed at approximately 350 sites.
“The need for more tightly integrated enterprise image and information systems, combined with the growing application of CT and MR into cardiac applications, necessitates that we continually evolve our products and the way we do business to most effectively provide solutions for our customers who are at the cutting edge of these changing markets,” said Makoto Kawaguchi, president and CEO, Fujifilm. “The acquisition of ProSolv enables Fujifilm to strengthen our existing product portfolio and our foundation for growth, and exemplifies FUFJILM Corporation’s long term commitment in the healthcare arena.”
ProSolv Founder and President Tom Feigenbaum said, “With the growing needs of our customers, combined with recent industry consolidation, we saw this as an opportune time to align with one of the industry leaders in PACS. Fujifilm will provide the additional resources that are necessary to ensure that our current and future customers alike continue to receive a stream of innovative clinical features backed by high quality support.” Feigenbaum will remain with ProSolv CardioVascular.
Investment and expansion in new clinical areas such as cardiology is one in a number of milestones for Fujifilm, and acquisition of ProSolv is an important step in delivering that complete vision.
The Synapse and ProSolv software applications share similar software technology approaches that have already enabled rapid systems integration, providing enhanced access to all clinical imaging data for customers using both products. The companies believe that with the integrated capabilities of the clinicians will see improved levels of efficiency and cost savings in the IT space from a uniform approach to storage and disaster recovery solutions.
“Fujifilm’s acquisition of ProSolv affords great opportunity for all of our customers,” said Bob Cooke, executive director of Marketing and Product Management, Fujifilm. “By combining the stability and corporate depth of Fujifilm, a proven leader in radiology PACS, with the cardiology expertise of ProSolv, both of our customer bases will benefit from access to new resources and technologies for the delivery of more effective patient care. This is yet another exciting step in our corporate and product evolution and will markedly enhance both our position in the market as well as our ability to continually deliver leading products.”
This is the first acquisition that FUJIFILM has made since launching the Synapse program and demonstrates, the company said, its commitment to a diverse expansion strategy.